A5 CONCLUD.

otherwise indicated. The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, Manassas, Virginia.

In the paragraph on page 77, lines 3-5, the text has been amended to read as follows:

A6

---The following materials have been deposited with the American Type Culture Collection, 10801 University Blvd., Manassas, Virginia, USA (ATCC): ---

In the Claims:

Claims 1-25 and 27-45 have been canceled without prejudice.

A7

Claim 26 remains pending:

26. (As filed) Isolated extracellular domain sequence of Apo-3 comprising amino acid residues 1 to 198 of SEQ ID NO:6.

The following claims have been added:

---46. A method of blocking or inhibiting Apo-3 receptor, comprising exposing mammalian cells expressing Apo-3 receptor to an effective amount of anti-Apo-3 antibody, wherein said antibody (a) comprises an antigen binding site which binds to an Apo-3 receptor polypeptide comprising amino acid residues 1 to 417 of SEQ ID NO:6 or an extracellular domain sequence of Apo-3 receptor polypeptide which comprises amino acid residues 25 to 198 of SEQ ID NO:6 and (b) blocks or inhibits Apo-3 receptor induced apoptosis in said mammalian cells or Apo-3 receptor activation of NF-kB in said mammalian cells.

A8

47. The method of claim 46 wherein said anti-Apo-3 antibody is a chimeric antibody.

48. The method of claim 46 wherein said anti-Apo-3 antibody is a humanized antibody.

49. The method of claim 46 wherein said anti-Apo-3 antibody is a human

antibody.

50. The method of claim 46 wherein said anti-Apo-3 antibody is a monovalent antibody.

51. The method of claim 50 wherein said monovalent antibody is a Fab fragment.

52. The method of claim 46 wherein said anti-Apo-3 antibody is labeled with a detectable moiety capable of directly or indirectly producing a signal.

53. The method of claim 52 wherein said detectable moiety is a radioisotope, fluorescent compound or chemiluminescent compound.

54. The method of claim 46 wherein said mammalian cells are exposed to said anti-Apo-3 antibody *in vivo*.

55. The method of claim 46 wherein said anti-Apo-3 antibody blocks or inhibits Apo-3 receptor induced apoptosis in said mammalian cells.

56. A method of blocking or inhibiting Apo-3 receptor, comprising exposing mammalian cells expressing Apo-3 receptor to an effective amount of Apo-3 receptor immunoadhesin, wherein said immunoadhesin (a) comprises an Apo-3 receptor polypeptide comprising amino acid residues 1 to 417 of SEQ ID NO:6 or a fragment thereof and (b) blocks or inhibits Apo-3 receptor induced apoptosis in said mammalian cells or Apo-3 receptor activation of NF-kB in said mammalian cells.

57. The method of claim 56 wherein said Apo-3 receptor immunoadhesin comprises an immunoglobulin constant region.

58. The method of claim 56 wherein said fragment of the Apo-3 receptor polypeptide comprises amino acid residues 1 to 198 of SEQ ID NO:6.

59. The method of claim 56 wherein said Apo-3 receptor immunoadhesin blocks or inhibits Apo-3 receptor induced apoptosis in said mammalian cells.

60. The method of claim 56 wherein said mammalian cells are exposed to said Apo-3 receptor immunoadhesin *in vivo*. ---